ArticleProceedings of the National Academy of Sciences of the United States of America2000
Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 81 citations in OpenAlex.
- Informatics Ecosystems to Advance the Biology of Glycans.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Soluble Heparin and Heparan Sulfate Glycosaminoglycans Interfere with Sonic Hedgehog Solubilization and Receptor Binding.Molecules (Basel, Switzerland) · 2019Article
- From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods.Molecules (Basel, Switzerland) · 2017Review
- Implementation of infrared and Raman modalities for glycosaminoglycan characterization in complex systems.Glycoconjugate journal · 2017Review
- An integrated approach using orthogonal analytical techniques to characterize heparan sulfate structure.Glycoconjugate journal · 2017Article
- Discovery of a heparan sulfate 3-O-sulfation specific peeling reaction.Analytical chemistry · 2015Article
- Structural Evidence for the Tetrameric Assembly of Chemokine CCL11 and the Glycosaminoglycan Arixtra™.Biomolecules · 2013Article
- Scientific considerations in the review and approval of generic enoxaparin in the United States.Nature biotechnology · 2013Article
- Glycomics approaches for the bioassay and structural analysis of heparin/heparan sulphates.Metabolites · 2012Article
- Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS.Analytical chemistry · 2012Article
- Harnessing glycomics technologies: integrating structure with function for glycan characterization.Electrophoresis · 2012Review
- Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin.Journal of medicinal chemistry · 2011Article
- Article
- Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics: insights into protein binding specificities.The Journal of biological chemistry · 2009Article
- Therapeutically targeting protein-glycan interactions.British journal of pharmacology · 2009Review
- Solid-phase synthesis of alpha-glucosamine sulfoforms with fragmentation analysis by tandem mass spectrometry.The Journal of organic chemistry · 2008Article
- Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Mass Spectrometry for the Analysis of Highly Charged Sulfated Carbohydrates.Current analytical chemistry · 2005Article
- Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.The Biochemical journal · 2004Article
- Rational design of low-molecular weight heparins with improved in vivo activity.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
Heparin- and heparan sulfate-like glycosaminoglycans (HLGAGs) represent an important class of molecules that interact with and modulate the activity of growth factors, enzymes, and morphogens. Of the many biological functions for this class of molecules, one of its most important functions is its interaction with antithrombin III (AT-III). AT-III binding to a specific heparin pentasaccharide sequence, containing an unusual 3-O sulfate on a N-sulfated, 6-O sulfated glucosamine, increases 1,000-fold AT-III's ability to inhibit specific proteases in the coagulation cascade. In this manner, HLGAGs play an important biological and pharmacological role in the modulation of blood clotting. Recently, a sequencing methodology was developed to further structure-function relationships of this important class of molecules. This methodology combines a property-encoded nomenclature scheme to handle the large information content (properties) of HLGAGs, with matrix-assisted laser desorption ionization MS and enzymatic and chemical degradation as experimental constraints to rapidly sequence picomole quantities of HLGAG oligosaccharides. Using the above property-encoded nomenclature-matrix-assisted laser desorption ionization approach, we found that the sequence of the decasaccharide used in this study is DeltaU(2S)H(NS,6S)I(2S)H(NS, 6S)I(2S)H(NS,6S)IH(NAc,6S)GH(NS,3S,6S) (+/-DDD4-7). We confirmed our results by using integral glycan sequencing and one-dimensional proton NMR. Furthermore, we show that this approach is flexible and is able to derive sequence information on an oligosaccharide mixture. Thus, this methodology will make possible both the analysis of other unusual sequences in HLGAGs with important biological activity as well as provide the basis for the structural analysis of these pharamacologically important group of heparin/heparan sulfates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.